Carbohydrate Macromolecule Targeting CD206 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods lack effective solutions for inflammasome-mediated disorders, which involve immune, autoimmune, and inflammatory diseases, as they do not specifically target the CD206 receptor on macrophages for targeted delivery of therapeutic or diagnostic agents.
Innovation Solution
Development of synthetic macromolecules with carbohydrate-based backbones, such as glycans with monosaccharide residues, that selectively bind to the CD206 receptor, allowing for targeted delivery of detectable moieties or therapeutic agents to inflammasome-mediated disorder sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic and treatment methods are used, then general immune and inflammatory conditions can be addressed, but specific targeting of CD206 receptor on macrophages is not achieved
Solution Approach 1:
The macromolecule is segmented into distinct functional modules: a carbohydrate-based backbone providing structural framework, multiple arms extending from the backbone, and receptor-binding compounds attached to the arms. This segmentation allows the CD206-targeting portion to be optimized independently for precision while the modular structure manages complexity through functional separation.
Solution Approach 2:
The carbohydrate-based backbone acts as an intermediary structure that connects the targeting function (receptor-binding compounds on arms) with the therapeutic or diagnostic payload. This mediator enables specific CD206 receptor binding while carrying the functional agents, resolving the contradiction between targeting precision and structural complexity.
2Reliability
If receptor-binding compounds are designed to bind specifically to CD206 receptor, then targeted delivery to macrophages is achieved, but the complexity of molecule design and synthesis increases
Solution Approach 1:
The carbohydrate-based backbone provides universal structural support and multiple attachment points for receptor-binding compounds. This universal platform can accommodate different specific CD206-binding ligands while maintaining the same core architecture, enabling standardized synthesis protocols and improving ease of manufacture while preserving binding specificity.
Solution Approach 2:
The invention allows optimization of specific parameters such as the number of arms, the type of carbohydrate residues, and the density of receptor-binding compounds without changing the fundamental molecular architecture. These parameter adjustments enable tuning of binding specificity while maintaining relatively simple synthesis procedures.
3Productivity
If multiple arms with receptor-binding compounds are attached to the carbohydrate backbone, then targeted delivery efficacy is enhanced, but the molecular weight and size of the carrier increase
Solution Approach 1:
The multi-armed structure concentrates the functional activity (receptor-binding compounds) at the peripheral regions (arms) while keeping the core carbohydrate backbone relatively lightweight. This local quality distribution enhances delivery efficiency at the target site while minimizing the overall molecular weight penalty.
Solution Approach 2:
The invention employs multiple arms with receptor-binding compounds, representing an excessive approach to ensure sufficient CD206 receptor engagement. This partial redundancy in binding sites compensates for the increased molecular weight by ensuring that enough of the macromolecule reaches and binds to target macrophages to achieve effective delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These carbohydrate-based macromolecules enable precise targeting and binding to CD206 receptors, facilitating effective diagnosis and treatment of inflammasome-mediated disorders by delivering detectable moieties or therapeutic agents directly to affected areas, enhancing diagnostic accuracy and therapeutic efficacy.
Implementation Method 1
synthetic macromolecules with carbohydrate-based backbones, such as glycans with monosaccharide residues, that selectively bind to the CD206 receptor
Data Source
AI summary
A method of diagnosing an inflammasome-mediated disorder includes administering a pharmaceutical composition to a subject. The composition includes a carrier molecule having a detectable moiety attached thereto. The carrier molecule includes a non-toxic carbohydrate-based backbone. The method also includes after the administering step, detecting a presence of the detectable moiety at a predetermined location in the subject.